0 Datasets
0 Files
Get instant academic access to this publication’s datasets.
Yes. After verification, you can browse and download datasets at no cost. Some premium assets may require author approval.
Files are stored on encrypted storage. Access is restricted to verified users and all downloads are logged.
Yes, message the author after sign-up to request supplementary files or replication code.
Join 50,000+ researchers worldwide. Get instant access to peer-reviewed datasets, advanced analytics, and global collaboration tools.
✓ Immediate verification • ✓ Free institutional access • ✓ Global collaborationJoin our academic network to download verified datasets and collaborate with researchers worldwide.
Get Free AccessOur analyses provide descriptive insights regarding the temporal changes of Hb, darbepoetin dose, and related parameters as ESRD approaches in participants of TREAT. Hb declined as much as 1-2 years prior to the development of ESRD, without biochemical evidence of iron deficiency. The most precipitous decline occurred in the months immediately prior to ESRD, despite administration of escalating doses of darbepoetin and in parallel with an increase in CRP.
Finnian R. Mc Causland, Brian Claggett, Marc A. Pfeffer, Emmanuel A. Burdmann, Kai‐Uwe Eckardt, Andrew S. Levey, John J.V. McMurray, Giuseppe Remuzzi, Ajay Singh, Scott D. Solomon, Robert D. Toto, Patrick S. Parfrey (2017). Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial. , 46(6), DOI: https://doi.org/10.1159/000485326.
Datasets shared by verified academics with rich metadata and previews.
Authors choose access levels; downloads are logged for transparency.
Students and faculty get instant access after verification.
Type
Article
Year
2017
Authors
12
Datasets
0
Total Files
0
Language
en
DOI
https://doi.org/10.1159/000485326
Access datasets from 50,000+ researchers worldwide with institutional verification.
Get Free Access